Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects

American Journal of Cardiology

Volumn 84, Issue 2, 1999, Pages 203-207

  Holmes, Michael B ^a   Sobel, Burton E ^a   Schneider, David J ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; PADGEM PROTEIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE; TIROFIBAN; TRYPSIN INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOSIS;

ADENOSINE DIPHOSPHATE; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOGEN; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PROTEIN BINDING; TYROSINE;

EID: 0032779426     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00235-0     Document Type: Article

References (20)

1. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 338:1998;1488-1497.
2. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 338:1998;1498-1505.
3. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 339:1998;436-443.
4. Sims P., Ginsburg D., Plump A.S., Shattil S.J. Effect of platelet activation on the conformation of the plasma membrane glycoprotein IIb-IIIa complex. J Biol Chem. 266:1991;7345-7352.
5. Schneider D.J., Taatjes D.J., Sobel B.E. Increased reactivity of platelets induced by fibrinogen independent of Its binding to the IIb-IIIa surface glycoprotein a potential contributor to cardiovascular risk . J Am Coll Cardiol. 33:1999;261-266.
6. Schneider D., Tracy P.B., Mann K.G., Sobel B.E. Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation. 96:1997;2877-2883.
7. Farrell T.P., Hayes K.B., Sobel B.E., Schneider D.J. The lack of augmentation by aspirin of inhibition of platelet reactivity by ticlopidine. Am J Cardiol. 83:1999;770-774.
8. Holmes MB, Sobel BE, Howard DB, Schneider DJ. Differences between activation thresholds for platelet P-selectin and glycoprotein IIb-IIIa expression and their clinical implications. Thromb Res In press.
9. Rand M.D., Lock J.B., van't Veer C., Gaffney D.P., Mann K.G. Blood clotting in minimally altered whole blood. Blood. 88:1996;1-14.
10. Phillips D.R., Teng W., Arfsten A., Nannizzi-Alaimo L., White M.M., Longhurst C., Shattil S.J., Randolph A., Jakubowski J.A., Jennings L.K., Scarborough R.M. Effect of Ca2+ on GP IIb-IIIa interactons with integrilin. Circulation. 96:1997;1488-1494.
11. Xia Z., Wong T., Liu Q., Kasirer-Friede A., Brown E., Frojmovic M.M. Optimally functional fluorescein isothiocyanate-labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation. Br J Haematol. 93:1995;204-214.
12. Barrett J.S., Murphy G., Peerlinck K., DeLepeleire I., Gould R.J., Panebianco D., Hand E., Deckmyn H., Vermylen J., Arnout J. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein IIb/IIIa receptor antagonist, in healthy men. Clin Pharm Ther. 56:1994;377-388.
13. Kereiakes D.J., Kleiman N., Ambrose J.A., Cohen M., Rodriguez S., Palabrica T., Herrmann H.C., Sutton J.M., Weaver W.D., McKee D.B., Fitzpatrick V., Sax F.L. Randomized, double-blind, placebo-controlled dose ranging study of tirofiban platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 27:1996;536-542.
14. Tcheng J.E., Harrington R.A., Kottke-Marchant K., Kleiman N.S., Ellis S.G., Kereiakes D.J., Mick M.J., Navetta F.I., Smith J.E., Worley S.J., Miller J.A., Joseph D.M., Sigmon K.N., Kitt M.M., du Mee C.P., Califf R.M., Topol E.J. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation. 91:1995;2151-2157.
15. Harrington R.A., Kleiman N., Kottke-Marchant K., Lincoff A.M., Tcheng J.E., Sigmon K.M., Joseph D., Rios G., Trainor K., Rose D., Greenberg C.S., Kitt M.M., Topol E.J., Califf R.M. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol. 76:1995;1222-1227.
16. Stenberg P.E., McEver R.P., Shuman M.A., Jacques Y.V., Bainton D.F. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol. 101:1985;880-886.
17. Monroe D.M., Roberts H.R., Hoffman M. Platelet procoagulant complex assembly in a tissue factor-initiated system. Br J Haematol. 88:1994;364-371.
18. Frelinger A., Du X., Plow E.F., Ginsburg M.H. Monoclonal antibodies to ligand-occupied conformers of glycoprotein IIb/IIIa alter receptor affinity, specificity and function. J Biol Chem. 266:1991;17106-17111.
19. Coller B.S., Beer J.H., Scudder L.E., Steinberg M.H. Collagen-platelet interactions evidence for a direct interaction of collagen with platelet GP Ia/IIa and an indirect interaction with platelet GP IIb/IIIa mediated by adhesive proteins . Blood. 74:1989;182-192.
20. Kroll M.H., Harris T.S., Moake J.L., Handin R.I., Schafer A.I. Von willebrand factor binding to platelet GP Ib initiates signals for platelet activation. J Clin Invest. 88:1991;1568-1573.